Literature DB >> 12663568

Assessing the shape of the glucose curve during an oral glucose tolerance test.

Otto Tschritter1, Andreas Fritsche, Fatemeh Shirkavand, Fausto Machicao, Hans Häring, Michael Stumvoll.   

Abstract

OBJECTIVE: The oral glucose tolerance test (OGTT) is used to define the status of glucose tolerance based on the plasma glucose level at 120 min. The purpose of the present study was to identify parameters that determine the shape of the plasma glucose course measured at 0, 30, 60, 90, and 120 min during an OGTT. RESEARCH DESIGN AND METHODS: OGTT data from 551 subjects (485 with normal glucose tolerance [NGT] and 66 with impaired glucose tolerance [IGT]) were analyzed. We distinguished between "monophasic," "biphasic," and unclassified glucose shapes. A "shape" index based on the extent and the direction of the plasma glucose change in the second hour allowed us to treat shape as a continuous variable.
RESULTS: In the biphasic group, the NGT-to-IGT ratio was slightly higher (173/20 vs. 209/40, P = 0.08) and the male-to-female ratio was lower (60/133 vs. 120/129, P = 0.0003). Subjects with a biphasic shape had significantly lower age, BMI, waist-to-hip ratio (WHR), HbA(1c), plasma glucose, and area under the insulin curve (insulin(AUC)) and a better estimated insulin sensitivity and secretion (using validated indexes) than monophasic subjects (all P < 0.05). By adjusting this shape index for glucose(AUC) (as continuous measure of glucose tolerance), correlations with age, BMI, WHR, HbA(1c), and insulin(AUC) were completely abolished. The adjusted shape index was still higher in female than in male subjects but lower in IGT than in NGT subjects (both P = 0.0003). Finally, we tested common polymorphisms in insulin receptor substrate (IRS)-1, IRS-2, calpain-10, hepatic lipase, and peroxisome proliferator-activated receptor-gamma for association with the shape index.
CONCLUSIONS: We conclude that the plasma glucose shape during an OGTT depends on glucose tolerance and sex. In addition, genetic factors seem to play a role. The shape index may be a useful metabolic screening parameter in epidemiological and genetic association studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663568     DOI: 10.2337/diacare.26.4.1026

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  53 in total

1.  Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility.

Authors:  Michael N Weedon; Peter E H Schwarz; Yukio Horikawa; Naoko Iwasaki; Thomas Illig; Rolf Holle; Wolfgang Rathmann; Thomas Selisko; Jan Schulze; Katherine R Owen; Julie Evans; Laura Del Bosque-Plata; Graham Hitman; Mark Walker; Jonathan C Levy; Mike Sampson; Graeme I Bell; Mark I McCarthy; Andrew T Hattersley; Timothy M Frayling
Journal:  Am J Hum Genet       Date:  2003-11       Impact factor: 11.025

2.  The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes.

Authors:  Heba M Ismail; Ping Xu; Ingrid M Libman; Dorothy J Becker; Jennifer B Marks; Jay S Skyler; Jerry P Palmer; Jay M Sosenko
Journal:  Diabetologia       Date:  2017-09-27       Impact factor: 10.122

3.  Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: results from two prospective cohorts.

Authors:  Akram Alyass; Peter Almgren; Mikael Akerlund; Jonathan Dushoff; Bo Isomaa; Peter Nilsson; Tiinamaija Tuomi; Valeriya Lyssenko; Leif Groop; David Meyre
Journal:  Diabetologia       Date:  2014-10-08       Impact factor: 10.122

4.  The Pathological Evolution of Glucose Response Curves During the Progression to Type 1 Diabetes in the TrialNet Pathway to Prevention Study.

Authors:  Heba M Ismail; Mario A Cleves; Ping Xu; Ingrid M Libman; Dorothy J Becker; Jennifer B Marks; Jay S Skyler; Jerry P Palmer; Jay M Sosenko
Journal:  Diabetes Care       Date:  2020-09-08       Impact factor: 19.112

5.  Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum.

Authors:  Caroline K Kramer; Chang Ye; Anthony J G Hanley; Philip W Connelly; Mathew Sermer; Bernard Zinman; Ravi Retnakaran
Journal:  Diabetologia       Date:  2015-03-12       Impact factor: 10.122

Review 6.  Methods for Measuring Risk for Type 2 Diabetes in Youth: the Oral Glucose Tolerance Test (OGTT).

Authors:  Melinda E Chen; Rebecca S Aguirre; Tamara S Hannon
Journal:  Curr Diab Rep       Date:  2018-06-16       Impact factor: 4.810

7.  The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in β-Cell Function in TODAY.

Authors:  Silva Arslanian; Laure El Ghormli; Joon Young Kim; Fida Bacha; Christine Chan; Heba M Ismail; Lorraine E Levitt Katz; Lynne Levitsky; Jeanie B Tryggestad; Neil H White
Journal:  Diabetes Care       Date:  2018-11-19       Impact factor: 19.112

8.  Patterns of changes in fasting plasma glucose, hemoglobin A1c and the area under the curve during oral glucose tolerance tests in prediabetic subjects: results from a 16-year prospective cohort study among first-degree relatives of type 2 diabetic patients.

Authors:  Shahla Safari; Masoud Amini; Ashraf Aminorroaya; Awat Feizi
Journal:  Acta Diabetol       Date:  2020-10-21       Impact factor: 4.280

9.  Novel Hypoglycemia Phenotype in Congenital Hyperinsulinism Due to Dominant Mutations of Uncoupling Protein 2.

Authors:  Christine T Ferrara; Kara E Boodhansingh; Eleonora Paradies; Giuseppe Fiermonte; Linda J Steinkrauss; Lisa Swartz Topor; Jose Bernardo Quintos; Arupa Ganguly; Diva D De Leon; Ferdinando Palmieri; Charles A Stanley
Journal:  J Clin Endocrinol Metab       Date:  2017-03-01       Impact factor: 5.958

Review 10.  Plasma glucose concentration and prediction of future risk of type 2 diabetes.

Authors:  Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.